Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy

Clinical and Experimental Allergy

Volumn 42, Issue 12, 2012, Pages 1745-1755

  Bonvalet, M ^a   Moussu, H ^a   Wambre, E ^b   Ricarte, C ^a   Horiot, S ^a   Rimaniol, A C ^a,c   Kwok, W W ^b   Horak, F ^d   de Beaumont, O ^a   Baron Bodo, V ^a   Moingeon, P ^a  

^a Stallergenes SA   (France)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c BERTIN TECHNOLOGIES   (France)

^d Department Vienna Challenge Chamber   (Austria)

Author keywords

Allergen; Biomarker; CD4+ T lymphocyte; Grass pollen; MHC class II tetramers; Sublingual immunotherapy

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; GRASS POLLEN EXTRACT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 7 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; GRASS POLLEN; HUMAN; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLARIZATION; POLLEN ALLERGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SUBLINGUAL IMMUNOTHERAPY; TH1 CELL; TH2 CELL;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANTIGENS, PLANT; CD4-POSITIVE T-LYMPHOCYTES; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; PLANT PROTEINS; POACEAE; POLLEN; PREDICTIVE VALUE OF TESTS; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 84870205595     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12015     Document Type: Article

References (38)

1. Canonica GW, Baena-Cagnani CE, Bousquet J et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-24.
2. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66:740-52.
3. Ippoliti F, De Santis W, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-21.
4. Moingeon P, Batard T, Fadel R et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65.
5. Cosmi L, Santarlasci V, Angeli R et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10-production. Clin Exp Allergy 2006; 36:261-72.
6. Scadding G, Durham SR. Mechanisms of sublingual smmunotherapy. Immunol Allergy Clin North Am 2011; 31:191-209.
7. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127:18-27.
8. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61:1184-90.
9. Ciprandi G, Cirillo I, Fenoglio D et al. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006; 6:1370-3.
10. Bohle B, Kinaciyan T, Gerstmayr M et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-13.
11. O'Hehir RE, Gardner LM, de Leon MP et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-{beta} and functional regulatory T cells. Am J Respir Crit Care Med 2009; 180:936-47.
12. Piconi S, Trabattoni D, Rainone V et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. J Immunol 2010; 185:7723-30.
13. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
14. Fujimura T, Yonekura S, Taniguchi Y et al. The induced regulatory T Cell level, defined as the proportion of IL-10+ Foxp3+ cells among CD25+ CD4+ leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report. Int Arch Allergy Immunol 2010; 153:378-87.
15. Fujimura T, Yonekura S, Horiguchi S et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol 2011; 139:65-74.
16. Rolinck-Werninghaus CKM, Liebke C, Lange J et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-41.
17. Dehlink E, Eiwegger T, Gerstmayr M et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36:32-9.
18. Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J Immunother 2002; 25:97-138.
19. Bateman EAL, Ardern-Jones MR, Ogg GS. Persistent central memory phenotype of circulating Fel d 1 peptide/DRB1*0101 tetramer-binding CD4+ T cells. J Allergy Clin Immunol 2006; 118:1350-6.
20. Macaubas C, Wahlstrom J, Galvão da Silva AP et al. Allergen-specific MHC class II tetramer+ cells are detectable in allergic, but not in nonallergic, individuals. J Immunol 2006; 176:5069-77.
21. Wambre E, Van Overtvelt L, Maillère B et al. Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: methodological aspects. Int Arch Allergy Immunol 2008; 146:99-112.
22. Van Overtvelt L, Wambre E, Maillere B et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC Class II peptide tetramers. J Immunol 2008; 180:4514-22.
23. Kwok WW, Roti M, DeLong JH et al. Direct ex vivo analysis of allergen-specific CD4+ T cells. J Allergy Clin Immunol 2010; 125(1407-1409):e1.
24. Kinnunen T, Nieminen A, Kwok WW et al. Allergen-specific naïve and memory CD4+ T cells exhibit functional and phenotypic differences between individuals with or without allergy. Eur J Immunol 2010; 40:2460-9.
25. DeLong JH, Simpson KH, Wambre E et al. Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 2011; 127(1211-1218):e3.
26. Wambre E, Bonvalet M, Bodo VB et al. Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4+ T cell responses. Clin Exp Allergy 2011; 41:192-203.
27. Wambre E, DeLong JH, James EA et al. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012; 129:544-51.
28. Tsuda H, Michimata T, Sakai M, Nagata K, Nakamura M, Saito S. A novel surface molecule of Th2- and Tc2-type cells, CRTH2 expression on human peripheral and decidual CD4+ and CD8+ T cells during the early stage of pregnancy. Clin Exp Immunol 2001; 123:105-11.
29. Horak F, Zieglmayer P, Zieglmayer R et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009; 124:471-7.
30. Moingeon P, Hrabina M, Bergmann KC et al. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. Int Arch Allergy Immunol 2008; 146:338-42.
31. Sone T, Tsukamoto K, Hirayama K et al. Two distinct class II molecules encoded by the genes within HLA-DR subregion of HLA-Dw2 and Dw12 can act as stimulating and restriction molecules. J Immunol 1985; 135:1288-98.
32. Kallinteris NL, Lu X, Blackwell CE et al. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther 2006; 6:1311-21.
33. Kwok WW, Gebe JA, Liu A et al. Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends Immunol 2001; 22:583-8.
34. Broide DH, Finkelman F, Bochner BS, Rothenberg ME. Advances in mechanisms of asthma, allergy, and immunology in 2010. J Allergy Clin Immunol 2011; 127:689-95.
35. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral Il-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-9.
36. Upadhyaya B, Yin Y, Hill BJ et al. Hierarchical IL-5 expression defines a subpopulation of highly differentiated human Th2 cells. J Immunol 2011; 187:3111-20.
37. Van Overtvelt L, Baron-Bodo V, Horiot S et al. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy 2011; 66:1530-7.
38. Zimmer A, Bouley J, Le Mignon M et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen immunotherapy. J Allergy Clin Immunol 2012; 129:1020-30.